These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity. Neyts J; De Clercq E Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749 [TBL] [Abstract][Full Text] [Related]
9. Combined treatment with 2'-nor-cGMP and ganciclovir against cytomegalovirus infection in a guinea pig model. Feng JS; Crouch JY; Tolman RL; Lucia HL; Hsiung GD Antiviral Res; 1992 Sep; 19(3):193-206. PubMed ID: 1332604 [TBL] [Abstract][Full Text] [Related]
10. Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC. Kloover JS; Vanagt WY; Stals FS; Bruggeman CA Antiviral Res; 1997 Jul; 35(2):105-12. PubMed ID: 9217247 [TBL] [Abstract][Full Text] [Related]
11. Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Fong CK; Cohen SD; McCormick S; Hsiung GD Antiviral Res; 1987 Jan; 7(1):11-23. PubMed ID: 3026243 [TBL] [Abstract][Full Text] [Related]
12. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Kern ER; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Quenelle DC Antimicrob Agents Chemother; 2004 Sep; 48(9):3516-22. PubMed ID: 15328119 [TBL] [Abstract][Full Text] [Related]
13. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Bravo FJ; Bernstein DI; Beadle JR; Hostetler KY; Cardin RD Antimicrob Agents Chemother; 2011 Jan; 55(1):35-41. PubMed ID: 21078944 [TBL] [Abstract][Full Text] [Related]
14. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. Stals FS; Zeytinoglu A; Havenith M; de Clercq E; Bruggeman CA Antimicrob Agents Chemother; 1993 Feb; 37(2):218-23. PubMed ID: 8383939 [TBL] [Abstract][Full Text] [Related]
15. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726 [TBL] [Abstract][Full Text] [Related]
16. The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Schleiss MR; Bernstein DI; McVoy MA; Stroup G; Bravo F; Creasy B; McGregor A; Henninger K; Hallenberger S Antiviral Res; 2005 Jan; 65(1):35-43. PubMed ID: 15652969 [TBL] [Abstract][Full Text] [Related]
17. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Kern ER Transplant Proc; 1991 Jun; 23(3 Suppl 3):152-5, discussion 155. PubMed ID: 1648821 [No Abstract] [Full Text] [Related]
18. Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model. Schleiss MR; Anderson JL; McGregor A Virol J; 2006 Mar; 3():9. PubMed ID: 16509982 [TBL] [Abstract][Full Text] [Related]
19. Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Kern ER; Rybak RJ; Hartline CB; Bidanset DJ Antivir Chem Chemother; 2001; 12 Suppl 1():149-56. PubMed ID: 11594682 [TBL] [Abstract][Full Text] [Related]
20. Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs. Lucia HL; Griffith BP; Hsiung GD Intervirology; 1984; 21(3):141-9. PubMed ID: 6327560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]